Date: 2014-03-13
Type of information: R&D agreement
Compound: immunotherapy products
Company: Medimmune (USA - global biologics arm of AstraZeneca (UK) - MD Anderson Cancer Center (USA - TX)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: immunotherapy
Disease:
Details: * On March 13, 2014, MedImmune, AstraZeneca’s global biologics research and development arm, has announced it has entered into a three-year translational and clinical research collaboration with The University of Texas MD Anderson Cancer Center to study therapies that unleash patients’ immune systems to attack their cancers through MD Anderson’s Moon Shots Program. This program is an ambitious effort to dramatically reduce cancer deaths by targeting eight cancers with the support of several new research platforms that provide infrastructure, expertise and technology.
MedImmune is conducting clinical trials using a new therapeutic paradigm that targets immune cells to improve their tumor-fighting ability, rather than targeting the tumor cell itself. Through the collaboration, MD Anderson will evaluate several of MedImmune’s immunotherapy molecules in a clinical setting in order to better understand how these molecules elicit immune response in patients. It is hoped that data collected from these studies will shed light on treatment-related changes to tumors, with the ultimate aim of identifying optimal combination therapies and developing biomarkers to guide and assess the safety and efficacy of MedImmune’s immunotherapy molecules.
Financial terms:
Latest news:
